David Reardon, MD

Articles

Interim Analysis Demonstrates Reassuring Toxicity Profile for Glioblastoma

July 24th 2020

David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.

Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm

David Reardon, MD

February 10th 2016

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.

Dr. David Reardon on Targeting Brain Tumors and Monitoring Resistances

David Reardon, MD

January 29th 2016

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment.

Dr. David Reardon on Treating Glioblastoma Patients With EGFRvIII-Mutations

David Reardon, MD

November 20th 2015

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor.

Rindopepimut, Combination Immunotherapy Treatments Have Potential in Brain Cancer

David Reardon, MD

June 2nd 2015

Rindopepimut for Recurrent Glioblastoma

David Reardon, MD

November 17th 2014

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.